Outlook Therapeutics (NASDAQ:OTLK) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Outlook Therapeutics (NASDAQ:OTLK) released its earnings results on Friday. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.01, MarketWatch Earnings reports.

Shares of NASDAQ:OTLK traded up $0.15 during midday trading on Friday, reaching $2.09. 746,599 shares of the company’s stock were exchanged, compared to its average volume of 3,565,887. The company’s 50 day simple moving average is $2.14 and its two-hundred day simple moving average is $1.70. The firm has a market capitalization of $362.84 million, a PE ratio of -1.67 and a beta of 0.46. Outlook Therapeutics has a 12 month low of $0.58 and a 12 month high of $4.26. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.13 and a current ratio of 1.13.

A number of research analysts have recently commented on the stock. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $6.00 price objective on shares of Outlook Therapeutics in a research report on Wednesday, February 17th. Zacks Investment Research lowered Outlook Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, February 10th.

In related news, COO Terry Dagnon sold 15,900 shares of the company’s stock in a transaction dated Tuesday, February 23rd. The shares were sold at an average price of $2.09, for a total value of $33,231.00. Following the sale, the chief operating officer now owns 1,127,857 shares of the company’s stock, valued at $2,357,221.13. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 4.00% of the stock is currently owned by insiders.

About Outlook Therapeutics

Outlook Therapeutics, Inc, a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, a proprietary ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age related macular degeneration and other retina diseases.

Further Reading: Why is the price-sales ratio important?

Earnings History for Outlook Therapeutics (NASDAQ:OTLK)

Receive News & Ratings for Outlook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Outlook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.